Two small clinical trials tested the safety of injecting stem cells into the brains of Parkinson's patients and found no adverse effects ...

The cell product was generally well tolerated and no severe adverse events related to the therapy were reported during the follow-up period of 18 months. There was no incidence of dyskinesia ...

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 ...